OssDsign publishes Annual Report 2023

OssDsign AB (publ) announces that the Annual Report for 2023 is now available as a PDF on the company's website, www.ossdsign.com. A PDF version is also attached to this press release.

“We enter 2024 as a pure play orthobiologics company with full focus on the U.S. market, fortified with excellent clinical results and an expanded indication for OssDsign Catalyst®” said Morten Henneveld, CEO, OssDsign AB.

For further information, please contact:

Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)

About OssDsign

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.

Tags: